WSGR logoWSGR logo

The unique history of Wilson Sonsini Goodrich & Rosati closely traces the birth and evolution of Silicon Valley.

For more than 60 years, Wilson Sonsini has represented technology pioneers associated with virtually every milestone innovation, as well as life sciences trailblazers shaping the future of healthcare.

Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.

Read More About Us

Wilson Sonsini secured a jury trial win for Google in a case alleging misuse of advertising technology.

Click for additional details.
Careers

We look for the best and brightest of tomorrow and develop careers from the ground up.

News and Featured Insights

Alerts
SCOTUS Ruling Calls into Question EU-U.S. Personal Data Flows
Podcasts
NextGen VC Podcast – Why the Future of Biotech Starts with the Brain
News Articles
Wilson Sonsini Attorneys Named to 2026 Lawdragon 500 Leading Energy Lawyers Guide
Leading Matters
Client Highlights
Wilson Sonsini Advises Standard Bots on $200 Million Series C
On June 11, 2026, Standard Bots, the largest manufacturer of AI-native, industrial robotics in the United States, announced a $200 million Series C led by RoboStrategy and existing investors, valuing the company at $1 billion. Standard Bots is also expanding its manufacturing footprint in New York, increasing its ability to design, assemble, and deploy American-made robots at scale. Wilson Sonsini Goodrich & Rosati advised Standard Bots on the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Beam Benefits on Acquisition by Principal Financial Group
On July 7, 2026, Principal Financial Group announced an agreement to acquire Beam Benefits, an employee benefits company serving more than 25,000 small businesses. Principal currently serves 180,000 employers, providing comprehensive retirement, benefits, and business owner solutions. The acquisition is expected to close in the latter half of 2026, subject to the completion of customary closing conditions and regulatory approvals. Wilson Sonsini Goodrich & Rosati advised Beam Benefits on the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Monogram on $40 Million Seed Round as Company Emerges from Stealth
On July 7, 2026, Monogram, a developer of an artificial intelligence (AI) application built around visual interface, emerged from stealth and announced a $40 million seed round led by DST Global and Lux Capital. Wilson Sonsini Goodrich & Rosati advised Monogram on the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Insilico on Collaboration with Takeda
On July 1, 2026, Insilico Medicine (Insilico),  a clinical-stage biotechnology company powered by generative artificial intelligence and automation, announced a strategic collaboration agreement with Takeda to use Insilico’s proprietary end-to-end platform, Pharma.AI, to advance drug candidates across various therapeutic areas, with a potential initial value of $600 million. Insilico will lead drug discovery, while Takeda will further development, including advancing candidates past clinical trials.
Learn More
Client Highlights
Wilson Sonsini Advises Arca on $64 Million Series A
On June 24, 2026, Arca Wealth (Arca), an AI-native wealth management company that brings personalized, advisor-led financial services, exited stealth and announced it secured $64 million across its seed round and Series A. The $48.5 million Series A was led by General Catalyst, with strong backing from Index Ventures and Venrock. Venrock also led the company's $15.5 million seed round. Wilson Sonsini Goodrich & Rosati advised Arca on the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Crinetics on Patent Matters Related to $10 Billion Acquisition by Vertex
On July 6, 2026, Vertex Pharmaceuticals and Crinetics Pharmaceuticals, a global pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases, announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10 billion, or approximately $8.8 billion net of estimated cash acquired. Wilson Sonsini Goodrich & Rosati is patent counsel to Crinetics and advised the company on patent matters related to the transaction.
Learn More
See More Leading Matters
The Life Sciences Report – June 2026

This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025.

Read More
WSGR logo
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.